Serratia marcescens vaccine in the treatment of malignant pleural effusion.
- Author:
Heling SHI
1
;
Yunzhong ZHU
;
Liyan XU
;
Zhe LIU
;
Yonghong YOU
;
Qiyi MENG
;
Xinyong ZHANG
;
Juntao XU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Vaccines; adverse effects; immunology; therapeutic use; Chest Pain; chemically induced; Dose-Response Relationship, Drug; Female; Fever; chemically induced; Humans; Male; Middle Aged; Pleural Effusion; drug therapy; immunology; Serratia marcescens; immunology; Time Factors; Treatment Outcome
- From: Chinese Journal of Oncology 2002;24(2):188-190
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of Serratia marcescens (S311) vaccine in the treatment of malignant pleural effusion.
METHODSThirty-four patients with malignant pleural effusion were given S311 as intrapleural injection with a dose of 10(9) U (0.32 mg) on D 1, 8 and 15, and observed for four weeks.
RESULTSThe overall response rate (CR + PR) was 97.1% (CR in 12 patients and PR in 21 patients). The systemic toxicity was mild, including fever (82.4%), pleuritic pain (50.7%), nansea (26.5%), dyspnea (17.5%) and chills (5.9%).
CONCLUSIONSerratia marcescens vaccine is effective for malignant pleural effusion, with tolerable toxic effects. Further study is warranted.
